86
Participants
Start Date
April 15, 2022
Primary Completion Date
December 31, 2025
Study Completion Date
June 30, 2026
Placebo
Capsule, administered once daily orally or via gastrostomy/gastrojejunostomy tube
Valbenazine
Capsule, administered once daily orally or via gastrostomy/gastrojejunostomy tube
Neurocrine Clinical Site, Brussels
Neurocrine Clinical Site, New York
Neurocrine Clinical Site, Baltimore
Neurocrine Clinical Site, Madrid
Neurocrine Clinical Site, Gulf Breeze
Neurocrine Clinical Site, Orlando
Neurocrine Clinical Site, Miami
Neurocrine Clinical Site, Columbus
Neurocrine Clinical Site, Cincinnati
Neurocrine Clinical Site, Farmington Hills
Neurocrine Clinical Site, Saint Paul
Neurocrine Clinical Site, Calambrone
Neurocrine Clinical Site, Chicago
Neurocrine Clinical Site, Oklahoma City
Neurocrine Clinical Site, Fort Worth
Neurocrine Clinical Site, Houston
Neurocrine Clinical Site, Aurora
Neurocrine Clinical Site, San Diego
Neurocrine Clinical Site, Portland
Neurocrine Clinical Site, Ẕerifin
Neurocrine Clinical Site, Stamford
Neurocrine Clinical Site, Boston
Neurocrine Clinical Site, Dallas
Neurocrine Clinical Site, Buenos Aires
Neurocrine Clinical Site, Buenos Aires
Neurocrine Clinical Site, Brasília
Neurocrine Clinical Site, Curitiba
Neurocrine Clinical Site, Porto Alegre
Neurocrine Clinical Site, Porto Alegre
Neurocrine Clinical Site, Milan
Neurocrine Clinical Site, Aguascalientes
Neurocrine Clinical Site, Gdansk
Neurocrine Clinical Site, Krakow
Neurocrine Clinical Site, Oświęcim
Neurocrine Clinical Site, Lisbon
Neurocrine Clinical Site, Lisbon
Neurocrine Clinical Site, Porto
Neurocrine Clinical Site, Barcelona
Lead Sponsor
Neurocrine Biosciences
INDUSTRY